Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $2.4 million.

  • Enanta Pharmaceuticals' Change in Accured Expenses rose 50299.25% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58000.0, marking a year-over-year increase of 10102.73%. This contributed to the annual value of $58000.0 for FY2025, which is 10102.73% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Change in Accured Expenses stood at $2.4 million, which was up 50299.25% from $2.5 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Change in Accured Expenses high stood at $4.7 million for Q3 2021, and its period low was -$6.7 million during Q4 2023.
  • In the last 5 years, Enanta Pharmaceuticals' Change in Accured Expenses had a median value of $792000.0 in 2023 and averaged $64473.7.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Change in Accured Expenses surged by 93985.15% in 2021, and later plummeted by 27787.93% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $4.2 million in 2021, then crashed by 256.89% to -$6.6 million in 2022, then fell by 2.08% to -$6.7 million in 2023, then skyrocketed by 56.8% to -$2.9 million in 2024, then surged by 183.09% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.5 million for Q2 2025, and -$2.0 million during Q1 2025.